Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVO-UWD-03 in Advanced Hepatocellular Carcinoma and Lung Cancer
NCT06653023Phase 1Suspended
- Sponsor
- Wondercel Therapeutics
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of REVO-UWD-03 in hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC), sponsored by Wondercel Therapeutics. Primary endpoints: Maximum Tolerated Dose at 1 month, Dose-Limiting Toxicities at 1 month and 1 more. Started Oct 2024; status: suspended.
02
Drugs
REVO-UWD-03
03
Conditions
hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06653023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06653023.